Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 7/20 | 0.42 |
| ▸ | JAK1 | P23458 | 7/20 | 0.42 |
| ▸ | JAK3 | P52333 | 7/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585149 | 0.83 | SMN1; SMN2 (0.53) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL22299275 | 0.83 | JAK2 (0.45) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL18390136 | 0.83 | SMN1; SMN2 (0.47) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| Hydrochloric Acid SCHEMBL25197889 | 0.81 | JAK1 (0.44) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| Hydrochloric Acid SCHEMBL15826105 | 0.81 | SMN1; SMN2 (0.52) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL24081331 | 0.80 | JAK1 (0.46) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL14808770 | 0.80 | SMN1; SMN2 (0.66) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL18713001 | 0.79 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL14842997 | 0.78 | SMN1; SMN2 (0.63) | HSD17B10SMN1; SMN2 | |
| SCHEMBL24081343 | 0.77 | JAK2 (0.44) | HSD17B10SMN1; SMN2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HSD17B10 3963/4885SMN1; SMN2 989/4885JAK2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.